BENICAR

LOE Approaching

olmesartan medoxomil

NDAORALTABLET
Approved
Apr 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

(ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of…

Indications (7)

hypertension in adultolderaloneother antihypertensive agentsto lower blood pressurehypertensionheart failure

Clinical Trials (5)

NCT01838850Phase 3Completed

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Started Apr 2013
344 enrolled
Essential Hypertension
NCT01309828Phase 3Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Started Mar 2011
153 enrolled
Safety
NCT01200407N/ATerminated

Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

Started Jun 2010
615 enrolled
Hypertension
NCT01033071Phase 3Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Started Jan 2010
1,071 enrolled
Essential Hypertension
NCT00996281Phase 3Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Started Oct 2009
837 enrolled
Essential Hypertension
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers